

# Microbiology

## Temporal upregulation of host surface receptors provides a window of opportunity for bacterial adhesion and disease

--Manuscript Draft--

<b>Manuscript Number:</b>	MIC-D-16-00285R2
<b>Full Title:</b>	Temporal upregulation of host surface receptors provides a window of opportunity for bacterial adhesion and disease
<b>Article Type:</b>	Review
<b>Section/Category:</b>	Host-microbe interaction
<b>Corresponding Author:</b>	Ronan F O'Toole, PhD University of Tasmania Hobart, TAS AUSTRALIA
<b>First Author:</b>	Rajendra KC
<b>Order of Authors:</b>	Rajendra KC Shakti D Shukla Eugene H Walters Ronan F O'Toole, PhD
<b>Abstract:</b>	<p>Host surface receptors provide bacteria with a foothold from which to attach, colonize and in some cases, invade tissue and elicit human disease. In this review, we discuss several key host receptors and cognate adhesins that function in bacterial pathogenesis. In particular, we examine the elevated expression of host surface receptors such as CEACAM-1, CEACAM-6, ICAM-1 and PAFR in response to specific stimuli. We explore how upregulated receptors, in turn, expose the host to a range of bacterial infections in the respiratory tract. It is apparent that exploitation of receptor induction for bacterial adherence is not unique to one body system, but is also observed in the central nervous, gastrointestinal, and urogenital systems. Prokaryotic pathogens which utilize this mechanism for their infectivity include <i>Streptococcus pneumoniae</i>, <i>Haemophilus influenzae</i>, <i>Neisseria meningitidis</i>, and <i>Escherichia coli</i>. A number of approaches have been used, in both in vitro and in vivo experimental models, to inhibit bacterial attachment to temporally-expressed host receptors. Some of these novel strategies may advance future targeted interventions for the prevention and treatment of bacterial disease.</p>

# Review

Temporal upregulation of host surface receptors provides a window of opportunity for bacterial adhesion and disease

Rajendra KC<sup>1</sup>, Shakti D. Shukla<sup>2,3</sup>, E. Haydn Walters<sup>1</sup>, **Ronan F. O'Toole<sup>1\*</sup>**

<sup>1</sup>School of Medicine, Faculty of Health, University of Tasmania, Hobart, TAS 7000, Australia

<sup>2</sup>School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, The University of Newcastle, Newcastle, NSW 2308, Australia

<sup>3</sup>Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, New Lambton Heights, Newcastle, NSW 2305, Australia.

\*Address for correspondence

Dr. Ronan F. O'Toole,  
School of Medicine, Faculty of Health,  
University of Tasmania,  
Medical Science 1, 17 Liverpool Street,  
Hobart TAS 7000, Australia.

Email: [ronan.otoole@utas.edu.au](mailto:ronan.otoole@utas.edu.au)

TEL: +61-3-6226 6974

Short Title: Upregulation of receptors for bacterial adhesion

## List of Abbreviations

AIEC:	adherent-invasive <i>E. coli</i>
BBB:	blood brain barrier
BM:	basement membrane
CEACAM:	carcinoembryonic antigen related cell adhesion molecule
CFTR:	cystic fibrosis transmembrane conductance regulator
ChoP:	phosphorylcholine
COPD:	chronic obstructive pulmonary disease
CUP:	chaperone-usheer pili
DAEC:	diffusely adhering <i>E. coli</i>
DAF:	decay-accelerating factor
ECM:	extracellular matrix
EHEC:	enterohemorrhagic <i>E. coli</i>
EMMPRIN:	extracellular matrix metalloproteinase inducer
EPEC:	enteropathogenic <i>E. coli</i>
ER:	endoplasmic reticulum
ETEC:	enterotoxigenic <i>E. coli</i>
Fn:	fibronectin
HCP:	hemorrhagic coli pilus
HIF-1:	hypoxia inducible factor 1
HPIV:	human parainfluenza virus
HSPG:	heparan sulfate proteoglycan
ICAM-1:	intercellular cell adhesion molecule 1
IFN $\gamma$ :	interferon-gamma
IgCAM:	immunoglobulin superfamily cell adhesion molecule
IL-1:	interleukin-1
IRF-1:	interferon regulatory factor 1 which binds
ISRE:	interferon-stimulated response element
LFA-1:	lymphocyte function-associated antigen 1
Ln:	laminin
Mac-1:	macrophage adhesion ligand 1
MAPK:	mitogen activated protein kinase
NF $\kappa$ B:	nuclear factor kappa B
NTHi:	non-typeable <i>Haemophilus influenzae</i>
OMP:	outer membrane protein
P pilus:	pyelonephritis-associated pilus
PAF:	platelet activating factor
PAFR:	platelet activating factor receptor
PavA:	pneumococcal adherence and virulence factor A

70 PECAM-1: platelet endothelial cell adhesion molecule 1  
71 PepO: pneumococcal endopeptidase O  
72 PfbA: plasmin-fibronectin binding protein A  
73 plgR: poly Immunoglobulin receptor  
74 Sp1: specificity protein 1  
75 TfP: type IV pili  
76 TGF- $\beta$ : transforming growth factor  
77 TNF $\alpha$ : tumour necrosis factor alpha  
78 UC: ulcerative colitis  
79 UPEC: uropathogenic *E. coli*  
80 UspA1: ubiquitous surface protein A1  
81 UTI: urinary tract infection

## Abstract

Host surface receptors provide bacteria with a foothold from which to attach, colonize and in some cases, invade tissue and elicit human disease. In this review, we discuss several key host receptors and cognate adhesins that function in bacterial pathogenesis. In particular, we examine the elevated expression of host surface receptors such as CEACAM-1, CEACAM-6, ICAM-1 and PAFR in response to specific stimuli. We explore how upregulated receptors, in turn, expose the host to a range of bacterial infections in the respiratory tract. It is apparent that exploitation of receptor induction for bacterial adherence is not unique to one body system, but is also observed in the central nervous, gastrointestinal, and urogenital systems. Prokaryotic pathogens which utilize this mechanism for their infectivity include *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Neisseria meningitidis*, and *Escherichia coli*. A number of approaches have been used, in both *in vitro* and *in vivo* experimental models, to inhibit bacterial attachment to temporally-expressed host receptors. Some of these novel strategies may advance future targeted interventions for the prevention and treatment of bacterial disease.

## Introduction

Mucosal surfaces of the respiratory, intestinal, and genitourinary tracts are important routes of entry into the host for bacterial pathogens (1). Multiple studies have shown that efficient binding between bacterial adhesins and host epithelial/endothelial surfaces is a prerequisite for establishing successful colonization (2). Therefore, the optimal presentation of host receptors for adhesion is critical for bacterial infection and subsequent disease. To date, much of the emphasis in the field of bacterial pathogenesis has been placed on the kinetics of expression of bacterial adhesins. This has often occurred in the context of assumed constitutive availability of cognate host surface receptors. However, it is becoming apparent that for bacterial diseases of a number of body systems including the respiratory, central nervous, gastrointestinal, and genitourinary systems, host receptors are appreciably induced in the presence of specific environmental or other stimuli.

In this review, we discuss the different types of host cell receptors, their interaction with their respective bacterial adhesins, and the regulation of their expression in different body sites. Finally, we provide an insight into potential clinically relevant strategies that are being

explored to inhibit the specific interactions between bacterial adhesins and temporally upregulated host cell receptors.

### **Host surface receptors for bacterial colonization**

Bacteria utilize a wide variety of molecules on host surfaces as docking sites for tissue adhesion and host colonization. Of particular interest, are the extracellular matrix (ECM) proteins, cell adhesion molecules (*e.g.* integrins, cadherins), and platelet-activating factor receptor (PAFR), which upon stimulation by certain environmental and/or immunogenic insults, undergo transient upregulation. This enhances bacterial adherence and subsequent tissue invasion (3-5).

ECM, the acellular proteinaceous part of animal connective tissue, constitutes the anchoring platform for epithelia, designated the basement membrane (BM), and also surrounds blood capillaries and neurons (6). It consists of collagen, elastin, fibrillin, laminin (Ln), fibronectin (Fn), vitronectin, thrombospondin, proteoglycans and hyaluronic acid. Besides its ubiquitous distribution, ECM biosynthesis is significantly enhanced following viral infections (*e.g.* influenza A virus) and traumatic injury (*e.g.* ligament rupture) as a natural response to tissue repair, and is therefore, an attractive target for adherence and invasion by several bacterial pathogens, such as *Neisseria meningitidis*, *Streptococcus pneumoniae*, and non-typeable *Haemophilus influenzae* (3, 7-11).

In addition to ECM components, cell adhesion molecules, including integrins, cadherins, selectins, and members of the immunoglobulin superfamily of cell adhesion molecules (IgCAMs), are also involved in bacterial adhesion (4, 12). Integrins are heterodimeric (composed of two subunits,  $\alpha$  and  $\beta$ ) transmembrane glycoproteins that attach cells to extracellular matrix proteins of the basement membrane or to ligands on other cells (13, 14). Several bacteria bind to integrins directly whereas others engage them via ECM proteins, such as fibronectin and collagen. Bacterial-integrin binding can trigger host intracellular signalling leading to actin cytoskeleton remodelling and subsequent bacterial invasion (4).

IgCAMs including, carcinoembryonic antigen-related cell adhesion molecule (CEACAM) and intercellular cell adhesion molecule 1 (ICAM-1), constitute the other major class of host cell receptors utilized by bacterial adhesion systems (4). The CEACAM family is a group of highly glycosylated intercellular adhesion molecules involved in signalling events that mediate key

cellular processes that include cell adhesion, proliferation, differentiation and tumour suppression (15). They comprise an N-terminal Ig variable (IgV)-like domain followed by up to six Ig(C) domains. Twelve different CEACAM proteins have been identified in humans to date with CEACAM-1, CEACAM-5 and CEACAM-6 found in epithelial cells, and CEACAM-3 present exclusively in granulocytes (16).

ICAM-1 (CD54) is a cell surface glycoprotein that serves as a counter-receptor for leucocyte  $\beta 2$  integrins, lymphocyte function associated antigen (LFA-1) (CD11a/CD18) and macrophage adhesion ligand 1 (Mac-1) (CD11b/CD18) (17). It is constitutively expressed in low levels on endothelium, fibroblasts and various epithelia (e.g. bronchial, intestinal, and urinary tract), however, its expression is markedly upregulated at sites of inflammation (18-22). Interactions between ICAM-1 and  $\beta 2$  integrins are known to have a central role in mediating leukocyte recruitment in the inflammatory response. This may lead to partial protection from invading pathogens but may also result in neutrophil-induced chronic epithelial injury (23, 24). A sustained inflammatory process may further upregulate adhesion receptors.

Finally, the other class of host cell receptor, platelet-activating factor receptor (PAFR) is a G-protein-coupled 7-transmembrane domain receptor, physiologically recognized by a phospholipid, platelet activating factor (PAF) (25). PAFR plays a role in a wide range of biological processes such as vasodilation, cell proliferation, angiogenesis, and regulation of the inflammatory response (25). Also, over the last decade, there has been increasing evidence emerging that PAFR is a major epithelial receptor used by specific respiratory and intestinal bacteria for adhesion to and also invasion of host epithelium (5, 26). Moreover, PAFR expression is inducible and is directly linked to increased susceptibility to infection by both Gram-positive and Gram-negative bacteria (26, 27).

## **Temporal host surface receptor upregulation in different body systems**

### **(i) Respiratory System**

Worldwide, respiratory diseases affect several hundred million people and cause approximately four million deaths annually (28). Two of the major contributors to respiratory-related deaths globally are chronic obstructive pulmonary disease (COPD) and acute respiratory infections. Major respiratory bacteria, such as nontypeable *Haemophilus*

*influenzae* (NTHi), *Streptococcus pneumoniae*, and *Moraxella catarrhalis*, are common asymptomatic colonizers of the upper respiratory tract, but under certain circumstances may disseminate and cause infections, such as otitis media, sinusitis, and lower respiratory tract ailments including bronchitis, pneumonia, and acute exacerbations of COPD (29-32). These species interact with and adhere to a variety of host cell receptors including ECM components and CEACAM-1, ICAM-1, and PAFR (5, 33, 34) (Figure 1).

*Pneumococci* are equipped with three different types of fibronectin-binding proteins: pneumococcal adherence and virulence factor A (PavA); plasmin-fibronectin binding protein A (PfbA); and pneumococcal endopeptidase O (PepO), which mediate adhesion to airway epithelia (10, 35, 36). Adherence of NTHi to fibronectin, laminin and type IV collagen is mediated by an autotransporter, *Haemophilus* adhesion and penetration protein (Hap) (37). Recently, NTHi lipoprotein P4 has demonstrated effective binding to nasopharyngeal, type II alveolar, and bronchial epithelial cells via fibronectin (7). Some respiratory viruses, such as Influenza A virus, Influenza B virus and Human Parainfluenza virus (HPIV) enhance the susceptibility to pneumococci and NTHi via upregulation of fibronectin and integrin expression. These viruses release neuraminidase which cleaves the sialic acid from latent transforming growth factor beta (TGF- $\beta$ ), thereby activating it. This stimulates the Smad signalling pathway resulting in the upregulation of both fibronectin and integrin expression (9).

P1, an outer membrane protein in NTHi is reported to be implicated in CEACAM-1 and CEACAM-5 binding, thus, facilitating adhesion and invasion of the nasopharynx and lower respiratory epithelium (38). Similarly, CEACAM-1-engaging adhesins have also been identified in *M. catarrhalis*. Ubiquitous surface protein A1 (UspA1), an outer membrane protein in *M. catarrhalis*, targets and interacts with CEACAM-1 facilitating adhesion and invasion of respiratory epithelium (39). NTHi and *M. catarrhalis* induce the expression of their own receptor, CEACAM-1, on host cells, thereby increasing the host susceptibility to bacterial infection (40).

*S. pneumoniae* and NTHi, along with some strains of *Pseudomonas aeruginosa*, a major bacterial pathogen in cystic fibrosis, share another common adhesin, known as phosphorylcholine (ChoP), in their cell wall (12, 41, 42). ChoP mimics PAF which is the natural arachidonic acid derived ligand for PAFR expressed on bronchial and alveolar epithelial cells. PAFR has been shown to be upregulated in human airway epithelial cells exposed to cigarette



smoke extract, as well as urban particulate matter (43-45). Furthermore, elevated PAFR expression resulted in higher levels of adhesion to bronchial epithelial cells by NTHi and *S. pneumoniae*, the major causes of acute exacerbations of COPD (46).

Although the regulation of PAFR expression in response to cigarette smoke still requires elucidation, the pathway for ICAM-1 enhancement has recently been delineated (47). Cigarette smoke results in higher levels of tumour necrosis factor- $\alpha$  (TNF $\alpha$ ) in the airway which increase expression of ICAM-1 via nuclear factor kappa B (NF $\kappa$ B). Upregulated ICAM-1 is exploited as a receptor for upper respiratory tract infection by the major group rhinoviruses (approximately 60% of serotypes) (48-51). Notably, ICAM-1 expression is further stimulated by rhinovirus infection, again via the NF $\kappa$ B pathway, which increases the susceptibility of airway epithelial cells to secondary bacterial infection (49). In addition to Rhinoviruses, NTHi has also been reported to utilize ICAM-1 for adherence to airway epithelium (52). Moreover, NTHi also upregulates the expression of the ICAM-1 receptor which successively increases the susceptibility to rhinoviral infection (53). ICAM-1 expression on respiratory epithelium is also elevated under different respiratory conditions, including COPD and bronchiectasis (22, 51, 54, 55).

Besides rhinovirus, other respiratory viruses are also implicated in predisposition to secondary bacterial infections (56). A variety of cytokines released, following viral infection, such as TNF $\alpha$ , interferon- $\gamma$  (IFN $\gamma$ ) and interleukin 1- $\beta$  (IL-1 $\beta$ ) can target the respiratory epithelium and induce the expression of adhesive molecules, including CEACAM-1 and PAFR (57). IFN $\gamma$ , in particular, is the most potent inflammatory cytokine that increases the expression of CEACAM-1, ICAM-1, and PAFR via the NF $\kappa$ B pathway (58). Notably, IFN $\gamma$  has also been reported to directly induce CEACAM-1 expression via activation of interferon regulatory factor 1 (IRF-1), which binds interferon-stimulated response element (ISRE) in the CEACAM-1 promoter (59).

## **(ii) Central Nervous System**

Temporal receptor upregulation is not unique to the respiratory system, and similar observations have been recorded in other body systems, including the endothelium in the central nervous system. The major central nervous system disease, meningitis, is manifested by a specific and limited number of bacterial pathogens, including *S. pneumoniae*, and *N. meningitidis*. The global incidence of pneumococcal meningitis was 0.1 million in children

younger than 5 years in 2000, whereas, the worldwide annual prevalence of meningococcal meningitis is 1.2 million with 135,000 deaths yearly (60, 61). Pneumococci utilize a similar set of host surface receptors, including PAFR, for both adherence to the respiratory epithelium and for penetrating the endothelial lining of the blood-brain barrier (BBB) (34). In addition, poly immunoglobulin receptor (pIgR), which transports immunoglobulins across mucosal epithelium, and platelet endothelial cell adhesion molecule-1 (PECAM-1), that is involved in leukocyte migration and angiogenesis in the endothelium, have also been found to be utilised by pneumococci for endothelium adhesion and invasion (62, 63). It has been proposed that pneumococcal infection in itself may upregulate pIgR and PECAM-1 expression via a PAFR mediated signalling mechanism (64). Pneumococcal cellular components, such as choline binding proteins and pneumolysin, or PAF synthesized by host innate immune response, are believed to mediate binding to PAFR. This interaction in turn stimulates multiple signal transduction pathways including phospholipase C, D, A2, mitogen-activated protein kinases (MAPKs) and the phosphatidylinositol-calcium second messenger system thereby, increasing the expression of pneumococcal adhesion receptors pIgR or PECAM-1 (64-66). In addition, pneumococcal pilus-1 adhesin RrgA and pilus-2 adhesin PitB have been implicated in pneumococci mediated adhesion and invasion of brain endothelial cells and respiratory epithelial cells (67-69).

Meningococci express a different set of adhesins to attach to and invade the cerebrovascular endothelial lining. Colony opacity-associated (Opa) protein and opacity class 5 protein, Opc, are outer membrane proteins, which mediate meningococcal adhesion specifically to CEACAM-1, heparan sulfate proteoglycan (HSPG) and integrins via the extracellular matrix proteins fibronectin and vitronectin (70, 71). Meningococci have been shown to trigger the expression of the CEACAM-1 receptor on primary endothelial cells via NF $\kappa$ B activation, which increases Opa/CEACAM-1-specific bacterial binding and internalization (72). In contrast, Opc primarily binds to ECM proteins, such as fibronectin and vitronectin, and is particularly implicated in host cell invasion of endothelial cells (73). Expression of fibronectin and its major receptor,  $\alpha$ 5 $\beta$ 1 integrin, is enhanced during cerebral hypoxia, and therefore, may predispose the host to meningococcal meningitis (74) (Figure 2).

Recently, a novel receptor, CD147, a member of the immunoglobulin superfamily, also called extracellular matrix metalloproteinase inducer (EMMPRIN) or Basigin, has been described as a major receptor that is recognized by the meningococcal type IV pilus (Tfp). *N. meningitidis*

utilizes CD147 for adhesion during infection (75). Interestingly, CD147 expression has been shown to be upregulated by hypoxia through a combined effect of transcription factors hypoxia inducible factor 1 (HIF-1) and specificity protein 1 (Sp1) on the activation of the CD147 gene promoter (76).

### (iii) Digestive System

Diarrhoea, the major gastrointestinal disorder, is the second leading cause of mortality worldwide among children under the age of five (77). In the gastrointestinal tract, various bacteria including different pathotypes of *E. coli* i.e. enteropathogenic *E. coli* (EPEC), enterotoxigenic *E. coli* (ETEC), adherent-invasive *E. coli* (AIEC), diffusely adhering *E. coli* (DAEC), and *Salmonella* spp. mediate their pathogenesis via adhesion to and/or invasion of intestinal epithelial cells (2). The chaperone-usher pathway (CUP) type I pilus adhesin, FimH, mediates adhesion to D-mannosyl residues of CEACAMs, including CEACAM-1, CEACAM-5, and CEACAM-6, and has been associated with EPEC and DAEC infections (78). In addition to type I pili, DAEC also expresses the CUP adhesins Afa/Dr which have been shown to recognize and bind the CEACAM-1, CEACAM-5 and CEACAM-6 receptors in the intestinal epithelial cells (79). Similar to the respiratory tract, CEACAMs in intestinal epithelial cells are normally expressed at low levels, which prevents their use by opportunistic pathogenic bacteria for attachment (80). However, in inflammatory conditions such as Crohn's disease, released cytokines TNF $\alpha$  and IFN $\gamma$  induce CEACAM-6 expression which promotes the adhesion to ileal epithelial cells by AIEC (81). Furthermore, overexpression of the endoplasmic reticulum (ER)-localised stress response chaperone protein Gp96 has been detected in Crohn's disease, and crucially is utilized as a receptor for the adhesin OmpA expressed by AIEC, thereby facilitating the bacterium's invasion (82).

Type IV pili such as PilS in *Salmonella enterica*, and haemorrhagic coli pilus (HCP) in enterohaemorrhagic *E. coli* (EHEC) mediate adherence to and invasion of intestinal epithelial cells leading to typhoid fever and haemorrhagic colitis, respectively (83, 84). *S. enterica* has been identified to utilize the adhesin PilS, interacting with the epithelial receptor, cystic fibrosis transmembrane conductance regulator (CFTR), allowing entry to the intestinal epithelial cells (85). Interestingly, CFTR gene expression has been shown to be induced in ulcerative colitis (UC), which might predispose an individual with this condition to subsequent *Salmonella* infection (86). On the other hand, EHEC has been demonstrated to bind to various

ECM proteins, including laminin, type IV collagen, and fibronectin via CUP and type IV pili (87, 88). Expression of the ECM component, fibronectin, has been found to be upregulated in intestinal epithelial cells during colitis, in both the acute phase as well as the recovery phase of the disease (89). In addition, PAFR is upregulated during intestinal inflammation via the hypoxia-inducible factor-1  $\alpha$  (26). The Gram-positive intestinal bacterial species, *Enterococcus faecalis*, exploits this upregulation of PAFR to translocate across the intestinal epithelial barrier (26) (Figure 3).

#### (iv) Urogenital System

The annual global burden of urinary tract infection (UTI) is estimated to be 150 million cases, resulting in an economic burden of more than 6 billion dollars per year (90). Uropathogenic *E. coli* (UPEC) is the most common bacterial pathogen associated with UTI, both uncomplicated and complicated. Uncomplicated UTIs typically affect individuals who are otherwise healthy and have no structural or neurological abnormalities and are differentiated into lower UTIs (cystitis) and upper UTIs (pyelonephritis). Complicated UTIs are associated with factors that compromise the urinary tract or host defense, including renal failure, urinary retention, pregnancy and the presence of urethral catheters (91, 92). UPEC has the ability to bind directly to kidney cells and bladder epithelium. The CUP pyelonephritis-associated (P) pilus adhesin, PapG, mediates binding to the  $\alpha$ -galactopyranosyl-(1-4)- $\beta$ -D-galactopyranoside moiety of glycolipids on the kidney cells (93).

Besides P pili, some UPEC strains express type I pili, which via the FimH adhesin confer binding to  $\alpha$ -D-mannosylated proteins, such as uroplakins on bladder epithelia, allowing colonization of the urinary tract (94). There is a paucity of data in relation to factors affecting uroplakin expression, although it has been shown to be associated with malignant transformation in the uroepithelium (95) (Figure 4).

In addition to pili, Afa/Dr-positive UPEC utilizes Dr adhesins to interact with type IV collagen in the kidney (96). The Dr adhesin has also been shown to bind to CEACAM-1, CEACAM-5 and CEACAM-6 receptor and decay accelerating factor (DAF) in bladder epithelial cells (79, 97). Interestingly, DAF expression is upregulated during pregnancy which predisposes pregnant women to UTI by Afa/Dr-positive UPEC (98). Furthermore, cell culture studies have confirmed that the extent of Afa/Dr-positive *E. coli* attachment to host epithelial cell is proportional to the level of DAF expression (99).

### **Inhibiting specific bacterial adhesin-host receptor interactions**

Bacterial infections, one of the major causes of morbidity and mortality worldwide, are becoming increasingly problematic to treat due to the growing acquisition of antibiotic resistance by major pathogens, as well as challenges to the generation of new clinically-approved antimicrobials (100). The potential for developing a novel alternative approach to prevent and/or treat life-threatening bacterial infections through interfering with bacterial/host tissue interfaces is timely. This could be achieved using a number of different strategies.

The first strategy is the inhibition/disruption of bacterial adhesin assembly by using small molecule inhibitors. Curlicides FN075 and BibC6 have been found to block the biogenesis of amyloid fibres curli, thereby inhibiting *in vitro* the UPEC biofilm formation (101). Moreover, UTI infection was significantly reduced *in vivo* by the pretreatment of UPEC with FN075 thereby suggesting the anti-virulence property of curlicides (101). Pilicide ec240, small molecule inhibitor of CUP pili has recently been reported to inhibit the assembly of type 1 and P pili in an *in vitro* culture of cystitis isolate of UPEC (102).

A second strategy involves inhibiting the upregulation of host cell receptors. Two important pathways for receptor upregulation, the NF $\kappa$ B and TGF- $\beta$ -Smad signalling pathways, could be potential therapeutic targets. The NF $\kappa$ B inhibitor, diferuloylmethane (curcumin) has been shown to significantly reduce the infectivity of the bacteria *N. gonorrhoeae*, *Helicobacter pylori* and *N. meningitidis* *in vitro* by blocking the expression of their cognate adhesion receptors (58, 103, 104). Similarly, in an *in vitro* study with human alveolar epithelial cells, the TGF $\beta$  inhibitor SB431542 has been reported to reduce infection associated with *S. pneumoniae*, *S. aureus* and NTHi following exposure to viral infections (9). *In vivo* studies are now needed to evaluate the therapeutic utility of NF $\kappa$ B and TGF- $\beta$  inhibitors.

Finally, the third and perhaps most utilized strategy is the disruption of the bacterial-host cell adhesive interaction with specific competitive inhibitors or receptor antagonists. Mannose derivative 4-methylumbelliferyl alpha-mannoside has been found to inhibit type 1 fimbriae-mediated binding of *E. coli* to guinea pig ileal epithelial cells (105). Also, methyl alpha-mannoside was reported to inhibit *E. coli* and *Salmonella* binding to glycoprotein CEACAM *in vitro* (78). Also, selective FimH binding mannosides have been indicated in preventing urinary tract infection in a preclinical murine model (106). *In vitro* studies have found that anti-CEACAM antibodies block the adhesion of *M. catarrhalis*, *N. meningitidis*, and NTHi to airway

epithelial cells (39, 71, 107). Also, NTHi adherence to A549 alveolar epithelial cells *in vitro*, was shown to be inhibited in a dose-dependent manner with increasing concentrations of anti-ICAM-1 monoclonal antibodies (52). An *in vivo* study conducted in chinchillas reported that anti-CEACAM-1 antibody YTH71.3 effectively blocked NTHi attachment to the nasopharynx (108).

In terms of specific receptor antagonists, a number of PAFR antagonists, such as Ginkgolide-B (BN52021), CV-3988, PCA-4248, CAS-99103-16-9, and WEB-2086, have been reported to block the attachment of bacterial pathogens to respiratory epithelium (12, 42, 109, 110). Of these, WEB-2086 has recently been demonstrated to significantly inhibit both NTHi and *S. pneumoniae* adherence to bronchial epithelial cells *in vitro* (46). WEB-2086 also caused a significant reduction in exotoxin ExoU-expressing *P. aeruginosa* bacterial load in both *in vitro* and *in vivo* infections of A549 human alveolar epithelial cells and mouse lungs, respectively (111). Besides WEB-2086, CAS-99103-16-9 has been shown to inhibit *Pseudomonas aeruginosa* infection in both *in vitro* and *in vivo* experimental model (42). In a mouse model of occupational exposure to welding fumes, PAF analogue CV-3988 significantly inhibited *S. pneumoniae* infection (112). In a mouse model of sickle cell disease, impact of PAFR antagonist BN-52021 was evaluated by challenge of PAFR knock out mice (113). Sickle cell disease was found associated with elevated levels of PAFR expression and BN-52021 was found to reduce the extent of pneumococcal disease (113).

There is good evidence that PAFR antagonists are well tolerated in humans based on earlier asthma clinical trials. SR27417 inhibited PAF-induced symptoms in patients with only minor side effects (114). Similarly, CV-3988 was not associated with any major adverse events at doses of 750-2000 µg/kg (115). In terms of returning to pre-treatment levels, no clinically evident adverse effects were reported for PAFR antagonist BN52021 nearly one year after a clinical trial in asthmatic children (116).

*In vitro* studies are robust, replicable, and economical for determining the mechanisms involved in adhesin-receptor interactions and also for measuring the inhibitory activity of new candidate drugs. However, the absence of cell-cell interactions, and the use of artificial culture conditions are among the main limitations (117). Outcomes from *in vitro* studies are not always applicable at the whole organism level. Hence, a priority is more *in vivo* work to establish the efficacy of the host receptor inhibitors in preventing bacterial infections and disease.

## Summary and Conclusions

All bacterial pathogens, including respiratory, intestinal and urinary tract pathogens, have evolved strategies to survive and colonize within their respective niches. They are equipped with adhesins that facilitate the binding, and in some cases, invasion of protective epithelial barriers. Host tissue can resist infection through reducing the presentation of surface receptors for bacterial adhesion. However, in the respiratory tract, certain stimuli such as viral infection, cigarette smoke exposure, and inflammation related to chronic illnesses including COPD, have been found to temporally heighten the expression of receptors. Among these are CAECAM-1, ICAM-1, and PAFR, that promote adherence by pathogens such as *H. influenzae* and *S. pneumoniae*. Upregulation of CAECAM-1 on endothelial cells enables breaching of the blood-brain barrier by *N. meningitidis* which is acutely linked to meningitis. In the intestine, Crohn's disease is associated with elevated expression of CAECAM-6 which promotes colonization by adherent-invasive *E. coli*. A number of inhibitors have been identified to date which block the adhesion of bacterial pathogens to upregulated host surface receptors indicating that such interactions could be amenable to therapeutic intervention. This may offer new avenues for the development of treatments for respiratory and other types of infections. However, validation of this approach, through further animal studies and subsequent investment in appropriate clinical trials, is needed.

## Funding information

The authors would like to acknowledge the support of the School of Medicine, Faculty of Health, University of Tasmania. RKC is a recipient of a Health Tasmania Graduate Research Scholarship.

## Conflicts of interest

None declared.

## Ethical approval

Not applicable.

## References

1. Kagnoff MF, Eckmann L. Epithelial cells as sensors for microbial infection. *The Journal of clinical investigation*. 1997;100(1):6-10.
2. Ribet D, Cossart P. How bacterial pathogens colonize their hosts and invade deeper tissues. *Microbes Infect*. 2015;17(3):173-83.
3. Singh B, Fleury C, Jalalvand F, Riesbeck K. Human pathogens utilize host extracellular matrix proteins laminin and collagen for adhesion and invasion of the host. *FEMS Microbiol Rev*. 2012;36(6):1122-80.
4. Hauck CR. Cell adhesion receptors - signaling capacity and exploitation by bacterial pathogens. *Med Microbiol Immunol*. 2002;191(2):55-62.
5. Shukla SD, Sohal SS, O'Toole RF, Eapen MS, Walters EH. Platelet activating factor receptor: gateway for bacterial chronic airway infection in chronic obstructive pulmonary disease and potential therapeutic target. *Expert Rev Respir Med*. 2015;9(4):473-85.
6. Chagnot C, Listrat A, Astruc T, Desvaux M. Bacterial adhesion to animal tissues: protein determinants for recognition of extracellular matrix components. *Cellular microbiology*. 2012;14(11):1687-96.
7. Su YC, Mukherjee O, Singh B, Hallgren O, Westergren-Thorsson G, Hood D, et al. Haemophilus influenzae P4 Interacts With Extracellular Matrix Proteins Promoting Adhesion and Serum Resistance. *J Infect Dis*. 2016;213(2):314-23.
8. Eberhard T, Virkola R, Korhonen T, Kronvall G, Ullberg M. Binding to human extracellular matrix by Neisseria meningitidis. *Infection and immunity*. 1998;66(4):1791-4.
9. Li N, Ren A, Wang X, Fan X, Zhao Y, Gao GF, et al. Influenza viral neuraminidase primes bacterial coinfection through TGF-beta-mediated expression of host cell receptors. *Proc Natl Acad Sci U S A*. 2015;112(1):238-43.
10. Pracht D, Elm C, Gerber J, Bergmann S, Rohde M, Seiler M, et al. PavA of Streptococcus pneumoniae modulates adherence, invasion, and meningeal inflammation. *Infection and immunity*. 2005;73(5):2680-9.
11. Neurath M. [Expression of tenascin, laminin and fibronectin following traumatic rupture of the anterior cruciate ligament]. *Z Orthop Ihre Grenzgeb*. 1993;131(2):168-72.
12. Grigg J, Walters H, Sohal SS, Wood-Baker R, Reid DW, Xu CB, et al. Cigarette smoke and platelet-activating factor receptor dependent adhesion of Streptococcus pneumoniae to lower airway cells. *Thorax*. 2012;67(10):908-13.
13. Barczyk M, Carracedo S, Gullberg D. Integrins. *Cell Tissue Res*. 2010;339(1):269-80.
14. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW. Ligand binding to integrins. *J Biol Chem*. 2000;275(29):21785-8.
15. Kuespert K, Pils S, Hauck CR. CEACAMs: their role in physiology and pathophysiology. *Curr Opin Cell Biol*. 2006;18(5):565-71.
16. Beauchemin N, Draber P, Dveksler G, Gold P, Gray-Owen S, Grunert F, et al. Redefined nomenclature for members of the carcinoembryonic antigen family. *Exp Cell Res*. 1999;252(2):243-9.
17. Staunton DE, Marlin SD, Stratowa C, Dustin ML, Springer TA. Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. *Cell*. 1988;52(6):925-33.
18. Tosi MF, Stark JM, Smith CW, Hamedani A, Gruenert DC, Infeld MD. Induction of ICAM-1 expression on human airway epithelial cells by inflammatory cytokines: effects on neutrophil-epithelial cell adhesion. *Am J Respir Cell Mol Biol*. 1992;7(2):214-21.
19. Frick AG, Joseph TD, Pang L, Rabe AM, St Geme JW, 3rd, Look DC. Haemophilus influenzae stimulates ICAM-1 expression on respiratory epithelial cells. *J Immunol*. 2000;164(8):4185-96.



20. Huang GT, Eckmann L, Savidge TC, Kagnoff MF. Infection of human intestinal epithelial cells with invasive bacteria upregulates apical intercellular adhesion molecule-1 (ICAM)-1 expression and neutrophil adhesion. *The Journal of clinical investigation*. 1996;98(2):572-83.
21. Chan RD, Greenstein SM, Sablay L, Alfonso F, Tellis V, Spitzer A, et al. Analysis of adhesion molecule expression by tubular epithelial cells using urine immunocytology. *Acta Cytol*. 1995;39(3):435-42.
22. Shukla SD, Mahmood MQ, Weston S, Latham R, Muller HK, Soha SS, et al. The main rhinovirus respiratory tract adhesion site (ICAM-1) is upregulated in smokers and patients with chronic airflow limitation (CAL). *Respir Res*. 2016;In press.
23. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 1994;8(8):504-12.
24. Sumagin R, Robin AZ, Nusrat A, Parkos CA. Transmigrated neutrophils in the intestinal lumen engage ICAM-1 to regulate the epithelial barrier and neutrophil recruitment. *Mucosal Immunol*. 2014;7(4):905-15.
25. Ishii S, Nagase T, Shimizu T. Platelet-activating factor receptor. *Prostaglandins Other Lipid Mediat*. 2002;68-69:599-609.
26. Keely S, Glover LE, Weissmueller T, MacManus CF, Fillon S, Fennimore B, et al. Hypoxia-inducible factor-dependent regulation of platelet-activating factor receptor as a route for gram-positive bacterial translocation across epithelia. *Mol Biol Cell*. 2010;21(4):538-46.
27. Grigg J. The platelet activating factor receptor: a new anti-infective target in respiratory disease? *Thorax*. 2012;67(9):840-1.
28. Ferkol T, Schraufnagel D. The global burden of respiratory disease. *Annals of the American Thoracic Society*. 2014;11(3):404-6.
29. Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. *Clin Microbiol Rev*. 2010;23(3):467-92.
30. Murphy TF, Parameswaran GI. *Moraxella catarrhalis*, a human respiratory tract pathogen. *Clin Infect Dis*. 2009;49(1):124-31.
31. Van Eldere J, Slack MP, Ladhani S, Cripps AW. Non-typeable *Haemophilus influenzae*, an under-recognised pathogen. *Lancet Infect Dis*. 2014;14(12):1281-92.
32. Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of *Streptococcus pneumoniae* virulence factors in host respiratory colonization and disease. *Nat Rev Microbiol*. 2008;6(4):288-301.
33. Hauck CR, Agerer F, Muenzner P, Schmitter T. Cellular adhesion molecules as targets for bacterial infection. *Eur J Cell Biol*. 2006;85(3-4):235-42.
34. Doran KS, Fulde M, Gratz N, Kim BJ, Nau R, Prasadarao N, et al. Host-pathogen interactions in bacterial meningitis. *Acta Neuropathol*. 2016;131(2):185-209.
35. Yamaguchi M, Terao Y, Mori Y, Hamada S, Kawabata S. PfbA, a novel plasmin- and fibronectin-binding protein of *Streptococcus pneumoniae*, contributes to fibronectin-dependent adhesion and antiphagocytosis. *J Biol Chem*. 2008;283(52):36272-9.
36. Agarwal V, Kuchipudi A, Fulde M, Riesbeck K, Bergmann S, Blom AM. *Streptococcus pneumoniae* endopeptidase O (PepO) is a multifunctional plasminogen- and fibronectin-binding protein, facilitating evasion of innate immunity and invasion of host cells. *J Biol Chem*. 2013;288(10):6849-63.
37. Fink DL, Green BA, St Geme JW, 3rd. The *Haemophilus influenzae* Hap autotransporter binds to fibronectin, laminin, and collagen IV. *Infection and immunity*. 2002;70(9):4902-7.
38. Tchoupa AK, Lichtenegger S, Reidl J, Hauck CR. Outer membrane protein P1 is the CEACAM-binding adhesin of *Haemophilus influenzae*. *Molecular Microbiology*. 2015;98(3):440-55.
39. Hill DJ, Virji M. A novel cell-binding mechanism of *Moraxella catarrhalis* ubiquitous surface protein UspA: specific targeting of the N-domain of carcinoembryonic antigen-related cell adhesion molecules by UspA1. *Mol Microbiol*. 2003;48(1):117-29.
40. Klaile E, Klassert TE, Scheffrahn I, Muller MM, Heinrich A, Heyl KA, et al. Carcinoembryonic antigen (CEA)-related cell adhesion molecules are co-expressed in the human lung and their

expression can be modulated in bronchial epithelial cells by non-typable *Haemophilus influenzae*, *Moraxella catarrhalis*, TLR3, and type I and II interferons. *Respir Res.* 2013;14:85.

41. Swords WE, Buscher BA, Ver Steeg li K, Preston A, Nichols WA, Weiser JN, et al. Non-typeable *Haemophilus influenzae* adhere to and invade human bronchial epithelial cells via an interaction of lipooligosaccharide with the PAF receptor. *Mol Microbiol.* 2000;37(1):13-27.
42. Barbier M, Oliver A, Rao J, Hanna SL, Goldberg JB, Alberti S. Novel phosphorylcholine-containing protein of *Pseudomonas aeruginosa* chronic infection isolates interacts with airway epithelial cells. *J Infect Dis.* 2008;197(3):465-73.
43. Mushtaq N, Ezzati M, Hall L, Dickson I, Kirwan M, Png KM, et al. Adhesion of *Streptococcus pneumoniae* to human airway epithelial cells exposed to urban particulate matter. *The Journal of allergy and clinical immunology.* 2011;127(5):1236-42.e2.
44. Shukla SD, Muller HK, Latham R, Sohal SS, Walters EH. Platelet-activating factor receptor (PAFr) is upregulated in small airways and alveoli of smokers and COPD patients. *Respirology.* 2016;21(3):504-10.
45. Shukla SD, Sohal SS, Mahmood MQ, Reid D, Muller HK, Walters EH. Airway epithelial platelet-activating factor receptor expression is markedly upregulated in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis.* 2014;9:853-61.
46. Shukla SD, Fairbairn RL, Gell DA, Latham RD, Sohal SS, Walters EH, et al. An antagonist of the platelet-activating factor receptor inhibits adherence of both nontypeable *Haemophilus influenzae* and *Streptococcus pneumoniae* to cultured human bronchial epithelial cells exposed to cigarette smoke. *Int J Chron Obstruct Pulmon Dis.* 2016;11:1647-55.
47. Poussin C, Laurent A, Peitsch MC, Hoeng J, De Leon H. Systems Biology Reveals Cigarette Smoke-Induced Concentration-Dependent Direct and Indirect Mechanisms That Promote Monocyte-Endothelial Cell Adhesion. *Toxicological sciences : an official journal of the Society of Toxicology.* 2015;147(2):370-85.
48. Greve JM, Davis G, Meyer AM, Forte CP, Yost SC, Marlor CW, et al. The major human rhinovirus receptor is ICAM-1. *Cell.* 1989;56(5):839-47.
49. Papi A, Johnston SL. Rhinovirus infection induces expression of its own receptor intercellular adhesion molecule 1 (ICAM-1) via increased NF-kappaB-mediated transcription. *J Biol Chem.* 1999;274(14):9707-20.
50. Staunton DE, Merluzzi VJ, Rothlein R, Barton R, Marlin SD, Springer TA. A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. *Cell.* 1989;56(5):849-53.
51. Ledford RM, Patel NR, Demenczuk TM, Watanyar A, Herbertz T, Collett MS, et al. VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds. *J Virol.* 2004;78(7):3663-74.
52. Avadhanula V, Rodriguez CA, Ulett GC, Bakaletz LO, Adderson EE. Nontypeable *Haemophilus influenzae* adheres to intercellular adhesion molecule 1 (ICAM-1) on respiratory epithelial cells and upregulates ICAM-1 expression. *Infection and immunity.* 2006;74(2):830-8.
53. Gulraiz F, Bellinghausen C, Bruggeman CA, Stassen FR. *Haemophilus influenzae* increases the susceptibility and inflammatory response of airway epithelial cells to viral infections. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology.* 2015;29(3):849-58.
54. Zandvoort A, van der Geld YM, Jonker MR, Noordhoek JA, Vos JT, Wesseling J, et al. High ICAM-1 gene expression in pulmonary fibroblasts of COPD patients: a reflection of an enhanced immunological function. *Eur Respir J.* 2006;28(1):113-22.
55. Chan SC, Shum DK, Tipoe GL, Mak JC, Leung ET, Ip MS. Upregulation of ICAM-1 expression in bronchial epithelial cells by airway secretions in bronchiectasis. *Respir Med.* 2008;102(2):287-98.
56. Bosch AA, Biesbroek G, Trzcinski K, Sanders EA, Bogaert D. Viral and bacterial interactions in the upper respiratory tract. *PLoS Pathog.* 2013;9(1):e1003057.

57. Avadhanula V, Rodriguez CA, Devincenzo JP, Wang Y, Webby RJ, Ulett GC, et al. Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent manner. *J Virol*. 2006;80(4):1629-36.
58. Griffiths NJ, Bradley CJ, Heyderman RS, Virji M. IFN-gamma amplifies NFkappaB-dependent Neisseria meningitidis invasion of epithelial cells via specific upregulation of CEA-related cell adhesion molecule 1. *Cellular microbiology*. 2007;9(12):2968-83.
59. Chen CJ, Lin TT, Shively JE. Role of interferon regulatory factor-1 in the induction of biliary glycoprotein (cell CAM-1) by interferon-gamma. *J Biol Chem*. 1996;271(45):28181-8.
60. Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, et al. Global epidemiology of invasive meningococcal disease. *Population health metrics*. 2013;11(1):17.
61. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. *Lancet (London, England)*. 2009;374(9693):893-902.
62. Iovino F, Molema G, Bijlsma JJ. Platelet endothelial cell adhesion molecule-1, a putative receptor for the adhesion of Streptococcus pneumoniae to the vascular endothelium of the blood-brain barrier. *Infection and immunity*. 2014;82(9):3555-66.
63. Iovino F, Molema G, Bijlsma JJ. Streptococcus pneumoniae Interacts with plgR expressed by the brain microvascular endothelium but does not co-localize with PAF receptor. *PLoS One*. 2014;9(5):e97914.
64. Iovino F, Brouwer MC, van de Beek D, Molema G, Bijlsma JJ. Signalling or binding: the role of the platelet-activating factor receptor in invasive pneumococcal disease. *Cellular microbiology*. 2013;15(6):870-81.
65. Shukla SD. Platelet-activating factor receptor and signal transduction mechanisms. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 1992;6(6):2296-301.
66. Iovino F, Seinen J, Henriques-Normark B, van Dijk JM. How Does Streptococcus pneumoniae Invade the Brain? *Trends Microbiol*. 2016;24(4):307-15.
67. Iovino F, Hammarlof DL, Garriss G, Brovall S, Nannapaneni P, Henriques-Normark B. Pneumococcal meningitis is promoted by single cocci expressing pilus adhesin RrgA. *The Journal of clinical investigation*. 2016b;126(8):2821-6.
68. Nelson AL, Ries J, Bagnoli F, Dahlberg S, Falker S, Rounioja S, et al. RrgA is a pilus-associated adhesin in Streptococcus pneumoniae. *Mol Microbiol*. 2007;66(2):329-40.
69. Bagnoli F, Moschioni M, Donati C, Dimitrovska V, Ferlenghi I, Facciotti C, et al. A second pilus type in Streptococcus pneumoniae is prevalent in emerging serotypes and mediates adhesion to host cells. *J Bacteriol*. 2008;190(15):5480-92.
70. Unkmeir A, Latsch K, Dietrich G, Wintermeyer E, Schinke B, Schwender S, et al. Fibronectin mediates Opc-dependent internalization of Neisseria meningitidis in human brain microvascular endothelial cells. *Mol Microbiol*. 2002;46(4):933-46.
71. Martin JN, Ball LM, Solomon TL, Dewald AH, Criss AK, Columbus L. Neisserial Opa Protein-CEACAM Interactions: Competition for Receptors as a Means of Bacterial Invasion and Pathogenesis. *Biochemistry*. 2016;55(31):4286-94.
72. Muenzner P, Naumann M, Meyer TF, Gray-Owen SD. Pathogenic Neisseria trigger expression of their carcinoembryonic antigen-related cellular adhesion molecule 1 (CEACAM1; previously CD66a) receptor on primary endothelial cells by activating the immediate early response transcription factor, nuclear factor-kappaB. *J Biol Chem*. 2001;276(26):24331-40.
73. Virji M. Pathogenic neisseriae: surface modulation, pathogenesis and infection control. *Nat Rev Microbiol*. 2009;7(4):274-86.
74. Milner R, Hung S, Erokwu B, Dore-Duffy P, LaManna JC, del Zoppo GJ. Increased expression of fibronectin and the alpha 5 beta 1 integrin in angiogenic cerebral blood vessels of mice subject to hypobaric hypoxia. *Mol Cell Neurosci*. 2008;38(1):43-52.

75. Bernard SC, Simpson N, Join-Lambert O, Federici C, Laran-Chich MP, Maissa N, et al. Pathogenic *Neisseria meningitidis* utilizes CD147 for vascular colonization. *Nat Med*. 2014;20(7):725-31.
76. Ke X, Fei F, Chen Y, Xu L, Zhang Z, Huang Q, et al. Hypoxia upregulates CD147 through a combined effect of HIF-1 $\alpha$  and Sp1 to promote glycolysis and tumor progression in epithelial solid tumors. *Carcinogenesis*. 2012;33(8):1598-607.
77. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. *Lancet (London, England)*. 2012;379(9832):2151-61.
78. Leusch HG, Drzeniek Z, Markos-Pusztai Z, Wagener C. Binding of *Escherichia coli* and *Salmonella* strains to members of the carcinoembryonic antigen family: differential binding inhibition by aromatic  $\alpha$ -glycosides of mannose. *Infection and immunity*. 1991;59(6):2051-7.
79. Berger CN, Billker O, Meyer TF, Servin AL, Kansau I. Differential recognition of members of the carcinoembryonic antigen family by Afa/Dr adhesins of diffusely adhering *Escherichia coli* (Afa/Dr DAEC). *Mol Microbiol*. 2004;52(4):963-83.
80. Ou G, Baranov V, Lundmark E, Hammarstrom S, Hammarstrom ML. Contribution of intestinal epithelial cells to innate immunity of the human gut--studies on polarized monolayers of colon carcinoma cells. *Scand J Immunol*. 2009;69(2):150-61.
81. Barnich N, Carvalho FA, Glasser AL, Darcha C, Jantschkeff P, Allez M, et al. CEACAM6 acts as a receptor for adherent-invasive *E. coli*, supporting ileal mucosa colonization in Crohn disease. *The Journal of clinical investigation*. 2007;117(6):1566-74.
82. Rolhion N, Barnich N, Bringer MA, Glasser AL, Ranc J, Hebuterne X, et al. Abnormally expressed ER stress response chaperone Gp96 in CD favours adherent-invasive *Escherichia coli* invasion. *Gut*. 2010;59(10):1355-62.
83. Zhang XL, Tsui IS, Yip CM, Fung AW, Wong DK, Dai X, et al. *Salmonella enterica* serovar typhi uses type IVB pili to enter human intestinal epithelial cells. *Infection and immunity*. 2000;68(6):3067-73.
84. Xicohtencatl-Cortes J, Monteiro-Neto V, Ledesma MA, Jordan DM, Francetic O, Kaper JB, et al. Intestinal adherence associated with type IV pili of enterohemorrhagic *Escherichia coli* O157:H7. *The Journal of clinical investigation*. 2007;117(11):3519-29.
85. Tsui IS, Yip CM, Hackett J, Morris C. The type IVB pili of *Salmonella enterica* serovar Typhi bind to the cystic fibrosis transmembrane conductance regulator. *Infection and immunity*. 2003;71(10):6049-50.
86. Lohi H, Makela S, Pulkkinen K, Hoglund P, Karjalainen-Lindsberg ML, Puolakkainen P, et al. Upregulation of CFTR expression but not SLC26A3 and SLC9A3 in ulcerative colitis. *Am J Physiol Gastrointest Liver Physiol*. 2002;283(3):G567-75.
87. Xicohtencatl-Cortes J, Monteiro-Neto V, Saldana Z, Ledesma MA, Puente JL, Giron JA. The type 4 pili of enterohemorrhagic *Escherichia coli* O157:H7 are multipurpose structures with pathogenic attributes. *J Bacteriol*. 2009;191(1):411-21.
88. Farfan MJ, Cantero L, Vidal R, Botkin DJ, Torres AG. Long polar fimbriae of enterohemorrhagic *Escherichia coli* O157:H7 bind to extracellular matrix proteins. *Infection and immunity*. 2011;79(9):3744-50.
89. Kolachala VL, Bajaj R, Wang L, Yan Y, Ritzenthaler JD, Gewirtz AT, et al. Epithelial-derived fibronectin expression, signaling, and function in intestinal inflammation. *J Biol Chem*. 2007;282(45):32965-73.
90. Harding G, Ronald A. The management of urinary infections; what have we learned in the past decade? *International journal of antimicrobial agents*. 1994;4(2):83-8.
91. Hooton TM. Clinical practice. Uncomplicated urinary tract infection. *N Engl J Med*. 2012;366(11):1028-37.
92. Nicolle LE. Complicated urinary tract infection in adults. *Can J Infect Dis Med Microbiol*. 2005;16(6):349-60.

93. Wright KJ, Hultgren SJ. Sticky fibers and uropathogenesis: bacterial adhesins in the urinary tract. *Future Microbiol.* 2006;1(1):75-87.
94. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nat Rev Microbiol.* 2015;13(5):269-84.
95. Olsburgh J, Harnden P, Weeks R, Smith B, Joyce A, Hall G, et al. Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. *J Pathol.* 2003;199(1):41-9.
96. Selvarangan R, Goluszko P, Singhal J, Carnoy C, Moseley S, Hudson B, et al. Interaction of Dr adhesin with collagen type IV is a critical step in Escherichia coli renal persistence. *Infection and immunity.* 2004;72(8):4827-35.
97. Muenzner P, Kengmo Tchoupa A, Klauser B, Brunner T, Putze J, Dobrindt U, et al. Uropathogenic E. coli Exploit CEA to Promote Colonization of the Urogenital Tract Mucosa. *PLoS Pathog.* 2016;12(5):e1005608.
98. Holmes CH, Simpson KL, Wainwright SD, Tate CG, Houlihan JM, Sawyer IH, et al. Preferential expression of the complement regulatory protein decay accelerating factor at the fetomaternal interface during human pregnancy. *J Immunol.* 1990;144(8):3099-105.
99. Selvarangan R, Goluszko P, Popov V, Singhal J, Pham T, Lublin DM, et al. Role of decay-accelerating factor domains and anchorage in internalization of Dr-fimbriated Escherichia coli. *Infection and immunity.* 2000;68(3):1391-9.
100. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. *P t.* 2015;40(4):277-83.
101. Cegelski L, Pinkner JS, Hammer ND, Cusumano CK, Hung CS, Chorell E, et al. Small-molecule inhibitors target Escherichia coli amyloid biogenesis and biofilm formation. *Nature chemical biology.* 2009;5(12):913-9.
102. Greene SE, Pinkner JS, Chorell E, Dodson KW, Shaffer CL, Conover MS, et al. Pilicide ec240 disrupts virulence circuits in uropathogenic Escherichia coli. *mBio.* 2014;5(6):e02038.
103. Wessler S, Muenzner P, Meyer TF, Naumann M. The anti-inflammatory compound curcumin inhibits Neisseria gonorrhoeae-induced NF-kappaB signaling, release of pro-inflammatory cytokines/chemokines and attenuates adhesion in late infection. *Biol Chem.* 2005;386(5):481-90.
104. Foryst-Ludwig A, Neumann M, Schneider-Brachert W, Naumann M. Curcumin blocks NF-kappaB and the motogenic response in Helicobacter pylori-infected epithelial cells. *Biochem Biophys Res Commun.* 2004;316(4):1065-72.
105. Firon N, Ashkenazi S, Mirelman D, Ofek I, Sharon N. Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast and intestinal epithelial cells. *Infection and immunity.* 1987;55(2):472-6.
106. Cusumano CK, Pinkner JS, Han Z, Greene SE, Ford BA, Crowley JR, et al. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. *Sci Transl Med.* 2011;3(109):109ra15.
107. Virji M, Evans D, Griffith J, Hill D, Serino L, Hadfield A, et al. Carcinoembryonic antigens are targeted by diverse strains of typable and non-typable Haemophilus influenzae. *Mol Microbiol.* 2000;36(4):784-95.
108. Bookwalter JE, Jurcisek JA, Gray-Owen SD, Fernandez S, McGillivray G, Bakaletz LO. A carcinoembryonic antigen-related cell adhesion molecule 1 homologue plays a pivotal role in nontypeable Haemophilus influenzae colonization of the chinchilla nasopharynx via the outer membrane protein P5-homologous adhesin. *Infection and immunity.* 2008;76(1):48-55.
109. Hergott CB, Roche AM, Naidu NA, Mesaros C, Blair IA, Weiser JN. Bacterial exploitation of phosphorylcholine mimicry suppresses inflammation to promote airway infection. *The Journal of clinical investigation.* 2015;125(10):3878-90.
110. Negro Alvarez JM, Miralles Lopez JC, Ortiz Martinez JL, Abellan Aleman A, Rubio del Barrio R. Platelet-activating factor antagonists. *Allergol Immunopathol (Madr).* 1997;25(5):249-58.
111. Mallet de Lima CD, da Conceicao Costa J, de Oliveira Lima Santos SA, Carvalho S, de Carvalho L, Albano RM, et al. Central role of PAFR signalling in ExoU-induced NF-kappaB activation. *Cellular microbiology.* 2014;16(8):1244-54.

112. Suri R, Periselneris J, Lanone S, Zeidler-Erdely PC, Melton G, Palmer KT, et al. Exposure to welding fumes and lower airway infection with *Streptococcus pneumoniae*. *The Journal of allergy and clinical immunology*. 2016;137(2):527-34.e7.
113. Miller ML, Gao G, Pestina T, Persons D, Tuomanen E. Hypersusceptibility to invasive pneumococcal infection in experimental sickle cell disease involves platelet-activating factor receptor. *J Infect Dis*. 2007;195(4):581-4.
114. Gomez FP, Roca J, Barbera JA, Chung KF, Peinado VI, Rodriguez-Roisin R. Effect of a platelet-activating factor (PAF) antagonist, SR 27417A, on PAF-induced gas exchange abnormalities in mild asthma. *Eur Respir J*. 1998;11(4):835-9.
115. Arnout J, van Hecken A, De Lepeleire I, Miyamoto Y, Holmes I, De Schepper P, et al. Effectiveness and tolerability of CV-3988, a selective PAF antagonist, after intravenous administration to man. *Br J Clin Pharmacol*. 1988;25(4):445-51.
116. Hsieh KH. Effects of PAF antagonist, BN52021, on the PAF-, methacholine-, and allergen-induced bronchoconstriction in asthmatic children. *Chest*. 1991;99(4):877-82.
117. Hartung T, Daston G. Are in vitro tests suitable for regulatory use? *Toxicological sciences : an official journal of the Society of Toxicology*. 2009;111(2):233-7.

**Figure 1.** Temporal upregulation of host surface receptors in the respiratory system.

Host surface receptors in the respiratory tract are upregulated in response to viral infection, exposure to cigarette and biomass fuel smoke, as well as inflammatory cytokines. Bacterial pathogens including non-typeable *Haemophilus influenzae*, *Streptococcus pneumoniae*, *Pseudomonas aeruginosa* and *Moraxella catarrhalis* exploit the upregulated receptors for attachment via their cognate adhesins. Strategies which have been found to inhibit such interactions are illustrated. PavA, pneumococcal adhesion and virulence A; PfbA, plasmin-fibronectin binding protein A; PepO, pneumococcal endopeptidase O; TGF $\beta$ R, transforming growth factor-beta receptor; COPD, chronic obstructive pulmonary disease; PAFR, platelet activating factor receptor; Hap, haemophilus adhesion and penetration; OMP, outer membrane protein; Anti-CEACAM Ab, anti-carcinoembryonic antigen cell adhesion molecule; UspA1, ubiquitous surface protein A1; IL-1, interleukin 1; TNF $\alpha$ , tumour necrosis factor-alpha; IFN $\gamma$ , interferon-gamma. Yellow, blue and orange coloured text boxes represent bacteria, inhibitors and factors affecting expression of host cell receptors, respectively. Green and red coloured texts represent bacterial adhesins and their cognate host cell receptors, respectively.

**Figure 2.** Temporal upregulation of host surface receptors associated with bacterial disease of the central nervous system.

Host receptors on endothelial surfaces are upregulated in response to viral infection, hypoxia, and inflammatory cytokines. Bacterial pathogens including *Streptococcus pneumoniae* and *Neisseria meningitidis* adhere to the upregulated receptors via their cognate adhesins which can facilitate invasion of the blood-brain barrier. Approaches which have been found to inhibit such interactions are illustrated. Opa, opacity-associated; Opc, opacity class 5; Tfp, type IV pili. Yellow, blue and orange coloured text boxes represent bacteria, inhibitors, and factors affecting expression of host cell receptors, respectively. Green and red coloured texts represent bacterial adhesins and their cognate host cell receptors, respectively.



**Figure 3.** Temporal upregulation of host surface receptors in the digestive system. Host surface receptors in the digestive tract are upregulated in response to Crohn's disease, colitis, and signals that include hypoxia. Bacterial pathogens including EPEC, ETEC, AIEC, DAEC, *Salmonella enterica* and *Enterococcus faecalis* bind to the upregulated receptors via their cognate adhesins. Strategies which have been found to inhibit such interactions are illustrated. CFTR, conductance fibrosis transmembrane receptor; EPEC, enteropathogenic *E. coli*; DAEC, diffusely adhering *E. coli*; EHEC, enterohemorrhagic *E. coli*; AIEC, adherently invasive *E. coli*; DAF, decay accelerating factor; HCP, hemorrhagic coli pilus. ChoP, phosphorylcholine. Yellow, blue and orange coloured text boxes represent bacteria, inhibitors, and factors affecting expression of host cell receptors, respectively. Green and red coloured texts represent bacterial adhesins and their cognate host cell receptors, respectively.

**Figure 4.** Temporal upregulation of host surface receptors in the urogenital system. Host surface receptors in the urogenital tract are upregulated in response to transitional cell carcinoma and pregnancy. UPEC binds to the upregulated receptors via its P pili, type I pili, and Afa/Dr adhesins. Strategies which have been found to inhibit the adhesive interactions are illustrated. P pili, pyelonephritis pili; UPEC, uropathogenic *E. coli*; NO, nitric oxide. Yellow, blue and orange coloured text boxes represent bacteria, inhibitors, and factors affecting expression of host cell receptors, respectively. Green and red coloured texts represent bacterial adhesins and their cognate host cell receptors, respectively.







